Cited by 655Medication Adherence and ComplianceDiabetes Management and EducationDiabetes Management and Research

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study

Open access

Peyrot, M., Barnett, A. H., Meneghini, L. F., Schumm‐Draeger, P.‐M.·2012·Diabetic Medicine

DOI 10.1111/j.1464-5491.2012.03605.xPMC PMC3433794

Open this paper in CoChat — free account Open PDF

Abstract

AIMS: To examine patient and physician beliefs regarding insulin therapy and the degree to which patients adhere to their insulin regimens. METHODS: Internet survey of 1250 physicians (600 specialists, 650 primary care physicians) who treat patients with diabetes and telephone survey of 1530 insulin-treated patients (180 with Type 1 diabetes, 1350 with Type 2 diabetes) in China, France, Japan, Germany, Spain, Turkey, the UK or the USA. RESULTS: One third (33.2%) of patients reported insulin omission/non-adherence at least 1 day in the last month, with an average of 3.3 days. Three quarters (72.5%) of physicians report that their typical patient does not take their insulin as prescribed, with a mean of 4.3 days per month of basal insulin omission/non-adherence and 5.7 days per month of prandial insulin omission/non-adherence. Patients and providers indicated the same five most common reasons for insulin omission/non-adherence: too busy; travelling; skipped meals; stress/emotional problems; public embarrassment. Physicians reported low patient success at initiating insulin in a timely fashion and adjusting insulin doses. Most physicians report that many insulin-treated patients do not have adequate glucose control (87.6%) and that they would treat more aggressively if not for concern about hypoglycaemia (75.5%). Although a majority of patients (and physicians) regard insulin treatment as restrictive, more patients see insulin treatment as having positive than negative impacts on their lives. CONCLUSIONS: Glucose control is inadequate among insulin-treated patients, in part attributable to insulin omission/non-adherence and lack of dose adjustment. There is a need for insulin regimens that are less restrictive and burdensome with lower risk of hypoglycaemia.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.2012.03605.x

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

FIGURE 1 Physician report: patient success with insulin treatment tasks (n = 1250)*†. *Percentage of physicians reporting that their patients are very successful (vs. somewhat successful, not very successful, not at all successful, ‘don’t know’). †Specialists and primary care physicians not significantly different for any measureCC BY · PubMed Central

FIGURE 2 Patient reports: impact of insulin treatment on life domains in patients with Type 1 (non-hatched) and Type 2 (hatched) diabetes mellitus (n = 1530). *Positive and negative responses differ significantly (P < 0.05); †reports from patients with Type 1 and Type 2 diabetes differ significantly (P < 0.05).CC BY · PubMed Central

FIGURE 3 Physician beliefs about insulin treatment (n = 1250). *Strongly agree or somewhat agree (vs. strongly disagree, somewhat disagree, neither, ‘don’t know’); †strongly agree or somewhat agree (vs. strongly disagree, somewhat disagree)CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
A systematic review of adherence with medications for diabetes
Cramer, J. A. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1218 · Cited by 1,203
Psychosocial problems and barriers to improved diabetes management: results of the Cross‐National Diabetes Attitudes, Wishes and Needs (DAWN) Study
Peyrot, M., Rubin, R. R., Lauritzen, T., Snoek, F. J., Matthews, D. R., & Skovlund, S. E. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01644.x · Cited by 931
Self-citation
Resistance to Insulin Therapy Among Patients and Providers
Peyrot, M. F., Rubin, R. R., Lauritzen, T., Skovlund, S. E., Snoek, F. J., Matthews, D. R., Landgraf, R., Kleinebreil, L., & Panel, O. B. O. T. I. D. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.11.2673 · Cited by 784
Self-citation
Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus
Morris, A. D., Boyle, D. I., McMahon, A. D., Greene, S. A., MacDonald, T. M., & Newton, R. W. (1997) · The Lancet · doi:10.1016/s0140-6736(97)06234-x · Cited by 507
Correlates of Insulin Injection Omission
Peyrot, M., Rubin, R. R., Kruger, D. F., & Travis, L. B. (2010) · Diabetes Care · doi:10.2337/dc09-1348 · Cited by 407
Self-citation
Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus
Rubin, R. R. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.04.012 · Cited by 403
Psychological insulin resistance: patient beliefs and implications for diabetes management
Brod, M. I., Kongsø, J. H., Alolga, S. L., & Christensen, T. L. (2008) · Quality of Life Research · doi:10.1007/s11136-008-9419-1 · Cited by 238
Insulin therapy for type 2 diabetes.
Swinnen, S. G., Hoekstra, J. B., & DeVries, J. H. (2009) · Diabetes Care · doi:10.2337/dc09-s318 · Cited by 181
Transition to insulin in Type 2 diabetes: family physicians' misconception of patients' fears contributes to existing barriers
Nakar, S., Yitzhaki, G., Rosenberg, R., & Vinker, S. (2007) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2006.02.004 · Cited by 159

Show all 22 references

Sorted by citations

Items 401–500 of 655

Safety, tolerability, pharmacokinetics and pharmacodynamics of GZR4 , a novel once‐weekly basal insulin, in healthy participants: A randomized trial
Tang, C., Su, R., Wan, L., Zhu, M., Pu, J., Hao, C., Zhao, J., He, A., Xie, T., Li, Y., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16250 · Cited by 6
Preferences, Expectations and Attitudes on Basal Insulin from Patient–Physician–Payer Perspective: A Multi-stakeholder Survey by the Italian Diabetes Society (ITA4P Study)
Fadini, G. P., Ciardullo, S., Perseghin, G., Giordano, C. S. D. S., Maddaloni, E., Buzzetti, R., Ghiani, M., & Avogaro, A. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01729-4 · Cited by 5
A post‐hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla‐300) versus 100 U/mL (Gla‐100) over wider nocturnal windows in individuals with type 2 diabetes on a basal‐only insulin regimen
Bolli, G. B., Wysham, C., Fisher, M., Chevalier, S., Cali, A. M. G., Leroy, B., & Riddle, M. C. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13515 · Cited by 5
Overcoming Barriers to Injectable Therapies: Development of the ORBIT Intervention Within a Behavioural Change Framework
McGuigan, K., Hill, A., McCay, D., O’Kane, M., & COATES, V. E. (2021) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2021.792634 · Cited by 5
Patient Perceptions of Satisfaction and Quality of Life Regarding Use of a Novel Insulin Delivery Device
Isaacs, D. M., Kruger, D. F., SHOGER, E., & Chawla, H. (2022) · Clinical Diabetes · doi:10.2337/cd22-0034 · Cited by 5
Expert Opinion on Current Trends in the Use of Insulin in the Management of People with Type 2 Diabetes from the South-Eastern European Region and Israel
Tabák, Á. G., Kempler, P., Guja, C., Eldor, R., Haluzı́k, M., Klupa, T., Παπάνας, Ν., Stoian, A. P., & Mankovsky, B. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01556-z · Cited by 5
Advances in insulin: a review of icodec as a novel once-weekly treatment for type 2 diabetes
Morales, J., King, A., Oser, S. M., & D’Souza, S. (2024) · Postgraduate Medicine · doi:10.1080/00325481.2024.2410694 · Cited by 5
Safety, efficacy, and early clinical experience of insulin degludec in Japanese people with diabetes mellitus: A first‐year report from Japan
Kaku, K., & Eid, M. A. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12348 · Cited by 5
Clinical and cost–effectiveness of insulin degludec: from clinical trials to clinical practice
Evans, M., & McEwan, P. C. (2015) · Journal of Comparative Effectiveness Research · doi:10.2217/cer.15.10 · Cited by 5
Lack of coordination between partners: investigation of Physician-Preferred and Patient-Preferred (4P) basal insulin titration algorithms in the real world
Zhang, T., Zhao, Y., Du, T., Zhang, X., Li, X., Liu, R., Wang, Y.-L., Chen, B., He, L., & Li, W. (2018) · Patient Preference and Adherence · doi:10.2147/ppa.s169000 · Cited by 5
The influence of demographic, social-educational determinants and diabetes management on agreement between glucometer and logbook and its impact on glycemic control in patients with type 1 diabetes: a follow-up study
Cavalcante, R. B. D. M., Matheus, A. S. D. M., Zanette, A., Braga, B., Duarte, B. P., Würdig, B., Maieron, D., Sorio, J. S., Bagatini, L., Cherit, M., et al. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0443-9 · Cited by 5
In Silico Examination of Initiation of Long-Acting Insulin Analogs Toujeo Compared to Lantus Under 3 Dosing Titration Rules in Virtual Type 2 Diabetes Subjects
Sieber, J., Weinheimer, M., Kongable, G., Riddle, S., Chang, Y.-Y., & Flacke, F. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819861586 · Cited by 5
Persons with type 2 diabetes and high insulin persistence were associated with a lower risk of mortality: A nationwide retrospective cohort study
Yen, F., Wei, J. C., Liu, J., Hsu, C., & Hwu, C. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13330 · Cited by 5
Physician related barriers towards insulin therapy at primary care centres in Trinidad: a cross-sectional study
Motilal, S. (2020) · BMC Family Practice · doi:10.1186/s12875-020-01271-1 · Cited by 5
Insulin adherence and the associated factors among patients with type 2 diabetes mellitus at the Hospital Queen Elizabeth II, Sabah
Yong, S. Y., Goh, G. M., & Loh, H. H. (2020) · Journal of Public Health · doi:10.1007/s10389-020-01409-6 · Cited by 5
Treatment Patterns and Outcomes Before and After Humulin R U-500 Initiation Among US Patients with Type 2 Diabetes Previously Prescribed ≤ 200 Units/day of U-100 Insulin
Chen, J., Borra, S., Huang, A., Fan, L., Pollom, R. D., & Hood, R. C. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01209-z · Cited by 5
Enabling Eating Detection in a Free-living Environment: Integrative Engineering and Machine Learning Study
Zhang, B., Deng, K., Shen, J., Cai, L., Ratitch, B., Fu, H., & Guan, Y. (2022) · Journal of Medical Internet Research · doi:10.2196/27934 · Cited by 5
Initiation of Basal Insulin Analog Treatment for Type 2 Diabetes and Reasons Behind Patients’ Treatment Persistence Behavior: Real-World Data from Germany
Mönnig, E., Perez‐Nieves, M., Hadjiyianni, I., Cao, D., Ivanova, J. I., & Klask, R. (2017) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-116386 · Cited by 5
Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study
CHENG, A. Y. Y., Harris, S. B., Giorgino, F., Seufert, J., Ritzel, R. A., Khunti, K. K., Lauand, F., Melas‐Melt, L., Westerbacka, J., Bosnyák, Z., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13901 · Cited by 5
Capacity and confidence building for general practitioners on optimum insulin use
Ahluwalia, A. I., Kalra, S., Deb, P., Gangopadhyay, K. K., & Gupta, S. (2019) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_635_19 · Cited by 5
Glucose-sensitive materials for delivery of antidiabetic drugs
Saeed, M., & ElShaer, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-08-102548-2.00009-3 · Cited by 5
Insulin Degludec, a Long-Acting Once-Daily Basal Analogue for Type 1 and Type 2 Diabetes Mellitus
Berard, L., & Macneill, G. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2014.02.019 · Cited by 5
Review of Clinical Profile of IDegAsp.
Unnikrishnan, A. G., Singh, A. K., Modi, K. D., Saboo, B., Garcha, S. C., & Rao, P. V. (2015) · PubMed · Cited by 5
Development and validation of a Chinese insulin medication literacy scale for patients with diabetes mellitus
Si, F., Feng, T., Shi, X., Chen, S., & Yang, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1477050 · Cited by 5
Efficacy and Safety of Once-Weekly Insulin Icodec in Indian Participants with Diabetes: Results from ONWARDS 1, 4, and 6 Studies
Mohan, V., Kesavadev, J., Murthy, L. S., Anil, G., Chandrappa, M., Kar, S., & Mishra, S. K. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01799-4 · Cited by 4
Design of a novel long-acting insulin analogs by acetylation modification and compared with insulin Icodec
Yu, M., Zhang, C., Xu, H., Dong, Y., Zhu, H., Xia, C., & Feng, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-94014-0 · Cited by 5
Safety and Functionality of a Novel Clinical Decision-Support Algorithm with Insulin Efsitora Alfa in Adults with Type 2 Diabetes: Early Feasibility Study
Katz, M., KAZDA, C. M., Xue, J., Frías, J. P., Brazg, R., Mitra, J., Gleissner, S. E., & Dassau, E. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.0051 · Cited by 4
The prevalence of diabetic retinopathy and its effect on social well-being and health related quality of life in children and young adults with type 1 diabetes
Hannula, V. (2015) · Cited by 4
Efficacy of iGlarLixi, a fixed‐ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as at high or low risk according to HEDIS measurements
Sugimoto, D. H., DEX, T. A., Stager, W., & Aroda, V. R. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13438 · Cited by 4
Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes in Malaysia: Results from a Prospective, Non-Interventional Real-World Study
Universiti Sains Malaysia, K. B., Mohamed, M., Lim, S. C., Mumtaz, M., Uppal, S., Mukherjee, D., Kassim, M. S. M., Sreedharan, S., Doraiswamy, A. M., Chong, K. M., et al. (2023) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.038.01.12 · Cited by 4
Current Perspective on the Potential Benefits of Smart Insulin Pens on Glycemic Control in Patients With Diabetes: Spanish Delphi Consensus
Moreno-Fernández, J., Díaz-Soto, G., Girbés, J., & Arroyo, F. J. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231178022 · Cited by 4
Effect of delay in treatment intensification in people with type 2 diabetes and suboptimal glycaemia after basal insulin initiation: A real‐world observational study
Shabnam, S., Abner, S. C., Gillies, C. L., Davies, M. J., DEX, T. A., Khunti, K. K., Webb, D. R., Zaccardi, F., & Seidu, S. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15337 · Cited by 4
Once‐Weekly Insulin Versus Once‐Daily Insulin for Type 1 Diabetes Treatment: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials
Altobaishat, O., Gadelmawla, A. F., Almohtasib, S., Suilik, H. A., Manasrah, A., Abouzid, M., Turkmani, M. M., & Abuelazm, M. T. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70048 · Cited by 4
Can a fixed-ratio combination of insulin degludec and liraglutide help Type 2 diabetes patients to optimize glycemic control across the day?
Simpson, R., & King, A. B. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1017562 · Cited by 4
The SimpleMix study with biphasic insulin aspart 30: a randomized controlled trial investigating patient-driven titration versus investigator-driven titration
Gao, Y., Luquez, C., Lynggaard, H., Andersen, H., & Saboo, B. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.960512 · Cited by 4
Should we Fear Insulin Therapy in the Treatment of Type 2 Diabetes?
Haslam, D. B. (2014) · The Open Obesity Journal · doi:10.2174/1876823701406010070 · Cited by 4
Intensifying Insulin Therapy in Type 2 Diabetes: Choices & Challenges.
Kumar, A., Kesavadev, J., Sethi, B. K., Jain, S. M., Guruprasad, C. S., & Shah, S. N. (2015) · PubMed · Cited by 4
Regular Insulin Administered With the V-Go Disposable Insulin Delivery Device in a Clinical Diabetes Setting: A Retrospective Analysis of Efficacy and Cost
SUTTON, D. R., Higdon, C., Carmon, M., & Abbott, S. (2016) · Clinical Diabetes · doi:10.2337/cd16-0021 · Cited by 4
Hypoglycaemia risk in the first 8 weeks of titration with insulin glargine 100 U/mL in previously insulin‐naive individuals with type 2 diabetes mellitus
Frier, B. M., Landgraf, W., Zhang, M., Bolli, G. B., & Owens, D. R. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13450 · Cited by 4
Az inzulinkezelés elkezdésének gyakorlati akadályai 2-es típusú cukorbetegekben – a „pszichológiai inzulinrezisztencia” leküzdése
Rácz, O., Linková, M., Jakubowski, K., Link, R., & Kuzmová, D. (2019) · Orvosi Hetilap · doi:10.1556/650.2019.31269 · Cited by 4
Short‐term cost‐utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9)
Pollock, R. F., Heller, S. R., Pieber, T. R., Woo, V. C., Gundgaard, J., Hallén, N., Luckevich, M., Tutkunkardas, D., Zinman, B., & On Behalf of the DEVOTE Study Group (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13730 · Cited by 4
Self-care, A1C and stigmatization as predictors of a negative perception of insulin among adults with type 2 diabetes: a hospital-based study in Turkey
Sürücü, H. A., Arslan, H. O., & Çetik, S. (2020) · Journal of Health Research · doi:10.1108/jhr-12-2019-0298 · Cited by 4
The Challenge of Adherence From Treatment-Care Regimens Among Patients With Chronic Diseases: A Qualitative Study
Vahedparast, H., Mohammadi, E., & Ahmadi, F. (2017) · Iranian South Medical Journal · doi:10.18869/acadpub.ismj.19.6.989 · Cited by 4
Switching “Real-World” Diabetes Patients to Degludec from Other Basal Insulins Provides Different Clinical Benefits According to Their Baseline Glycemic Control
Tentolouris, N., Knudsen, S. T., Lapolla, A., Wolden, M. L., Haldrup, S., & Schultes, B. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00916-7 · Cited by 4
Assessment of basal insulin adherence using 2 methodologies among Texas Medicaid enrollees with type 2 diabetes
Zhang, H., Barner, J. C., Moczygemba, L. R., & Rascati, K. L. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.11.1434 · Cited by 5
Inpatient hyperglycemia management: the opportunities of a new basal insulin
Simioni, N. (2016) · Italian Journal of Medicine · doi:10.4081/itjm.2016.681 · Cited by 4
Adverse Changes in HbA1c, Body Weight and Insulin Use in People with Type 1 Diabetes Mellitus Following Dapagliflozin Discontinuation in the DEPICT Clinical Trial Programme
Gordon, J. P., Danne, T., BERESFORD-HULME, L. M., Bennet, H., Tank, A., Edmonds, C., THOREN, F. A., Scheerer, M. F., & McEwan, P. C. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00807-z · Cited by 4
Cost-effectiveness of insulin icodec for the treatment of type 2 diabetes in Canada
Garcia, D., Mau, G., Singh, S. R., Spence, M., Jensen, M. S., & Goldenberg, R. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2551449 · Cited by 3
Guideline-Directed Medical Therapy for Diabetic Kidney Disease: Advances in Primary and Secondary Prevention
Verma, S., Katwal, S., Akula, H. R., Inamdar, A., Kundukulam, S. S., Khan, M., Satti, A. B. A. Q., Menon, S., & Rai, M. (2026) · Cureus · doi:10.7759/cureus.101867 · Cited by 3
Unmet Needs in Insulin-Treated Diabetes Management
Hirsch, I. B., & Parkin, C. G. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251396121 · Cited by 3
Hypoglycemic events and glycemic control effects between NPH and premixed insulin in patients with type 2 diabetes mellitus: A real-world experience at a comprehensive specialized hospital in Ethiopia
Sendekie, A. K., Netere, A. K., & Belachew, E. A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0275032 · Cited by 3
Diabetes in Orthopaedic Sports Medicine Surgeries Standard Review
Morriss, N. J., & Brophy, R. H. (2023) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-22-01112 · Cited by 3
Real-world effectiveness of iGlarLixi in individuals with T2D sub-optimally controlled on oral anti-diabetic drugs with or without basal insulin in daily practice in Saudi Arabia (EMPOWER study)
Jammah, A. A., Roushdy, N., Gamil, M., Diab, N. A., Abdelmonaem, N., Safarini, S., Gadallah, M., Zaid, N. A., Shihadeh, Y., Saeed, M., et al. (2024) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2024.100164 · Cited by 3
Prevalence of Hypoglycemia and Its Determinants Among Diabetes Patients on Insulin Treatment at Tepi General Hospital, Southwest, Ethiopia
Ambaye, A. S., Mengiste, F., Demise, N., Derseh, M. T., Abebe, A., Yayehrad, A. T., & Endalifer, B. L. (2024) · Patient Preference and Adherence · doi:10.2147/ppa.s458091 · Cited by 3
Pharmacokinetic Properties of Once‐Weekly Insulin Icodec in Children and Adolescents With Type 2 Diabetes
Name, M. A. V., Ásbjörnsdóttir, B., Gomes, M. M., Hale, P. M., Udupa, K., VINTHER, S. M., Wolf, R. M., & Ribel‐Madsen, R. (2025) · Pediatric Diabetes · doi:10.1155/pedi/5514927 · Cited by 3
Assessment of basal insulin adherence in people with type 2 diabetes in telemonitoring: Post-hoc analysis of novel data modalities including insulin injection data
Nørlev, J. T. D., Kronborg, T., Jensen, M. H., Rana, P., Vestergaard, P., & Hangaard, S. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112191 · Cited by 3
Perceptions of Suboptimal Insulin Dosing from People with Diabetes and Healthcare Professionals in Germany
Ponce-Ibarra, A., Hennies, N., Newson, R. S., Artime, E., Spaepen, E., & Kempe, H. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01767-y · Cited by 3
Glycaemic control after connected insulin pen initiation in people living with diabetes: Results from a real‐world setting
Adolfsson, P., Guerci, B., Hartvig, N. V., Kaas, A., Knudsen, N., & Mader, J. K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70051 · Cited by 3
Understanding Insulin Pump Therapy
Dajkovich, G., & Barkley, T. W. (2015) · Journal of Community Health Nursing · doi:10.1080/07370016.2015.1057064 · Cited by 3
A Short-Acting GLP-1 Analog or Prandial Insulin to Supplement Basal Insulin?—Moving Toward Personalized Management of Type 2 Diabetes Mellitus
Hirsch, I. B., Schneider, D., King, A., Polonsky, W. H., Reid, T., Shubrook, J. H., Verderese, C. A., Wallace, J. I., & Riddle, M. C. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.05.2763 · Cited by 3
Addressing barriers to effective basal insulin therapy.
Mohan, V., John, M., Baruah, M. P., & Bhansali, A. (2014) · PubMed · Cited by 3
Insulin glargine 300 units/mL: a guide for healthcare professionals involved in the management of diabetes
Strong, J. L., Kruger, D. F., & Novak, L. M. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1288614 · Cited by 3
Technique d’injection de l’insuline : que font les patients diabétiques en France ?
Sauvanet, J.-P., & Halimi, S. (2017) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(17)30098-6 · Cited by 3
¿La insulina es un todoterreno?
Cuenca, A. M. C. (2021) · doi:10.52102/insulina/art-4 · Cited by 3
Cómo podemos optimizar la insulinización
Cosiales, P. B. (2021) · doi:10.52102/insulina/art-3 · Cited by 3
Clinical Use of Insulin Glargine 300 U/mL in Adults with Type 2 Diabetes: Hypothetical Case Studies
Harris, S. B., Parente, E. B., & Karalliedde, J. J. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01247-7 · Cited by 3
Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 ( BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial
McCrimmon, R. J., Home, P., CHENG, A. Y. Y., Giorgino, F., Fonseca, V. A., Souhami, E., Alvarez, A., Picard, P., & Rosenstock, J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14825 · Cited by 3
Turkish validity and reliability of the Diabetes Medication Self-Efficacy Scale
Kavuran, E., & Türkoğlu, N. (2022) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.18.5.2022.1187 · Cited by 3
Evaluating the clinical effectiveness and safety of insulin glargine 300 U/ mL in individuals with type 2 diabetes uncontrolled on basal insulin: A real‐world evidence study from Saudi Arabia ( EVOLUTION )
Malki, F. A., Damanhoury, B. E., Othman, A., Alghamdi, Z., AlQahtani, M., Madgy, A., & Chouikrat, M. Z. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15178 · Cited by 3
A Three-Step Data-Driven Methodology to Assess Adherence to Basal Insulin Therapy in Patients With Insulin-Treated Type 2 Diabetes
Nørlev, J. T. D., Kronborg, T., Jensen, M. H., Vestergaard, P., Hejlesen, O. K., & Hangaard, S. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231222007 · Cited by 3
Toward once-monthly insulin therapy via synergy in two pharmacokinetic protractors: Fc-conjugation and fatty acid acylation
Zaykov, A. N., Gelfanov, V. M., Tagmose, T. M., Demozay, D., Manfé, V., Rohlfs, R., Rivir, M., Pérez–Tilve, D., Finan, B., & DiMarchi, R. D. (2024) · RSC Chemical Biology · doi:10.1039/d4cb00078a · Cited by 3
IDegLira improves time in range in a cohort of patients with type 2 diabetes: TiREX study
Malighetti, M. E., Molteni, L., Orsi, E., Serra, R., Gaglio, A., Mazzoleni, F., Russo, F., & Bossi, A. C. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02361-7 · Cited by 3
Insulin delivery devices in diabetes management: Applications and advancements
Yang, R., Yang, Z., Chi, J., & Ya, Z. (2025) · Intelligent Pharmacy · doi:10.1016/j.ipha.2025.02.002 · Cited by 3
Predictors of insulin adherence among patients with type 2 diabetes: a cross-sectional study
Muhammad, H. J., Hussein, R. M., Zmezim, M., Al‐Hussainy, A. F., Farhood, H. H., Naser, I. H., & Alghurabi, H. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2517697 · Cited by 3
A comparison of the clinical courses of type 2 diabetic patients whose basal insulin preparation was replaced from insulin glargine 100 units/mL to insulin glargine biosimilar or 300 units/mL: a propensity score-matched observation study
Ito, H., Tsugami, E., Ando, S., Araki, R., Matsumoto, S., Uemura, K., Nishio, S., Antoku, S., Yamasaki, T., Mori, T., et al. (2018) · Journal of Drug Assessment · doi:10.1080/21556660.2018.1513846 · Cited by 3
Psychological Insulin Resistance: Key Factors and Intervention
Jang, Y. J. (2021) · Journal of Korean Diabetes · doi:10.4093/jkd.2021.192.196.192 · Cited by 3
Biphasic Insulin Aspart 30 in Insulin-Naive People with Type 2 Diabetes in Non-western Nations: Results from a Regional Comparative Multinational Observational Study (A 1 chieve)
Shah, S. N., Yang, W., Hasan, M. I., Malek, R., Bech, O. M., & Home, P. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0074 · Cited by 3
PEGylated insulin Lispro (LY2605541): clinical overview of a new long-acting basal insulin analog in the treatment of Type 2 diabetes mellitus
Røder, M. E. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.1043270 · Cited by 3
Biomimetic Approach to Designing Adhesive Hydrogels: From Chemistry to Application
Li, Y., & Lee, B. P. (2015) · Springer series in biomaterials science and engineering · doi:10.1007/978-3-319-22861-7_15 · Cited by 3
Risk Factors for Fatal Hyperglycaemia Confirmed by Forensic Postmortem Examination - A Nationwide Cohort in Sweden
Walz, L., Jönsson, A. K., Zilg, B., Östgren, C. J., & Druid, H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164950 · Cited by 3
Insulin Degludec/Liraglutide
Baker, D. E. (2017) · Hospital Pharmacy · doi:10.1177/0018578717715383 · Cited by 3
Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: A 12‐month comparison by concomitant sulphonylurea and/or glinide use
Terauchi, Y., Riddle, M. C., Hirose, T., Koyama, M., Cheng, X., Takahashi, Y., & Bolli, G. B. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13414 · Cited by 3
Injectable therapy in type 2 diabetes mellitus: strategies to improve therapeutic adherence
Gurova, O. Y., Fadeev, V. V., & Maloletkina, E. S. (2019) · Diabetes Mellitus · doi:10.14341/dm9603 · Cited by 3
Consensus on Choice of Insulin Pen Devices in Routine Clinical Practice in India
Gupta, A., Phatak, S., Rao, Y. S., Ramesh, J., & Sanyal, D. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0494 · Cited by 3
Real-world data on the use of insulin glargine 300 U/mL in Japanese patients with type 1 diabetes: twelve-month results from a post-marketing surveillance study (X-STAR study)
Matsuhisa, M., Odawara, M., Hirose, T., Koshida, R., Senda, M., Tanaka, Y., & Terauchi, Y. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1810665 · Cited by 3
Indian reality of managing type 2 diabetes: an expert review of global and national guidelines for optimum insulin use
Kumar, A., Sharma, S., Gupta, A., Dasgupta, A., Asirvatham, A. J., Talwalkar, P., Das, A., & Mohan, V. (2020) · Journal of Diabetology · doi:10.4103/jod.jod_59_20 · Cited by 3
Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled ( glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan‐O randomized trial
Davies, M. J., Rosenstock, J., Ali, A., Russell-Jones, D. L., Souhami, E., PALMER, K. D., Ji, C. F., Niemoeller, E., & SKOLNIK, N. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14543 · Cited by 4
Premixed insulin regimens for type 2 diabetes
Τσάπας, Α., Karagiannis, T., & Bekiari, E. (2015) · Endocrine · doi:10.1007/s12020-015-0821-5 · Cited by 3
The relationship between shot-blocker and vibration device and its effect on reducing pain and discomfort during insulin injection therapy: A randomized controlled trial
Abdulyemmah, A. D., & Majeed, H. M. (2025) · International Journal of Pediatrics and Adolescent Medicine · doi:10.4103/ijpam.ijpam_66_25 · Cited by 2
Economic evaluation of liraglutide vs dulaglutide or oral semaglutide in patients with type 2 diabetes mellitus: a systematic review
Wang, L., Wang, F., Wang, Y., & Zhao, Q. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01927-x · Cited by 2
Understanding insulin dose deviations in people with type 2 diabetes receiving telemonitoring
Nørlev, J. T. D., Kronborg, T., Jensen, M. H., Vestergaard, P., & Hangaard, S. (2025) · Primary care diabetes · doi:10.1016/j.pcd.2025.10.001 · Cited by 2
Cost-Effectiveness of Once-Weekly Insulin Icodec versus Daily Basal Insulins in Chinese Adults with T2DM: A Treatment-Background Stratified Analysis
Xie, Z., Deng, W., Liang, Z., Xie, Y., Chen, J., & Cao, W. (2025) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s539841 · Cited by 2
Inhaled Insulin Decoded: Dispelling Myths and Presenting Clinical Evidence
Kesavadev, J., Thacker, H. P., Deshpande, N., Asirvatham, A. J., Saboo, B., Kalra, P., Shaikh, S. S., Joshi, A. S., Chawla, M. S., Agarwal, S., et al. (2025) · Cureus · doi:10.7759/cureus.100247 · Cited by 3
Potential Role of Inhaled Insulin in the Management of Gestational Diabetes Mellitus and Pediatric Type 1 Diabetes
Laffel, L. M., & Valent, A. M. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251403591 · Cited by 2
Enhancing Insulin Therapy Adherence Through Technology: Which Needles Do People with Diabetes Prefer?
Gentile, S., Fiorentino, R., Lettieri, M., Guarino, G., Marino, G., Tommasi, E., Frison, V., Satta, E., Chiarello, M., Caccavale, G., et al. (2026) · Diabetology · doi:10.3390/diabetology7030056 · Cited by 2
What primary care physicians think about insulin initiation in type 2 diabetes:a field-based study
Ak, M., Sucaklı, M. H., Canbal, M., & Koşar, Y. (2015) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-1307-44 · Cited by 2
The Multigenerational Legacy of Diabetes, Emotional Reactions, and Insulin Adherence
Scollan‐Koliopoulos, M. (2020) · Journal of Social Health and Diabetes · doi:10.1055/s-0040-1722421 · Cited by 2
Exploring the Experiences and Perspectives of Insulin Therapy in Type 2 Diabetes via Web-Based UK Diabetes Health Forums: Qualitative Thematic Analysis of Threads
Allen-Taylor, M., Ryan, L., Winkley, K., & Upsher, R. J. (2022) · JMIR Diabetes · doi:10.2196/34650 · Cited by 3
Scientific advisory on nocturnal hypoglycemia in insulin-treated patients with diabetes: Recommendations from Indian experts
Chawla, M. S., Chawla, P., Saboo, B., Chawla, R., Gangopadhyay, K. K., Kalra, S., Aravind, S. R., Sinha, B., Shah, T. U., Kesavadev, J., et al. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102587 · Cited by 2
Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy
Ren, H., Berry, S., Malkin, S. J. P., Hunt, B., & Bain, S. C. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-070473 · Cited by 4

Authors: Peyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐.
Affiliations: Johns Hopkins University (US)
Heart of England NHS Foundation Trust (GB)
University of Miami (US)
München Klinik Bogenhausen (DE)
Corresponding author: Peyrot, M.
ORCID: Peyrot, M.
Meneghini, L. F.
Venue: Diabetic Medicine
Publisher: Wiley
Published: 2012-04-16
Volume: 29
Issue: 5
Pages: 682-689
ISSN: 0742-3071 (ISSN-L)
1464-5491
DOI: 10.1111/j.1464-5491.2012.03605.x
PMC: PMC3433794
OpenAlex: W1613501644
Cited by: 655
References: 22
Citations by year: 2026: 29 · 2025: 41 · 2024: 61 · 2023: 43 · 2022: 42 · 2021: 43 · 2020: 53 · 2019: 49 · 2018: 52 · 2017: 48 · 2016: 52 · 2015: 50 · 2014: 46 · 2013: 35 · 2012: 8
FWCI: 38.62
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Diabetic Medicine (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
Topics: Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords: insulin therapy, insulin adherence, insulin omission, barriers to adherence, patient beliefs, physician beliefs, type 1 diabetes, type 2 diabetes, glycemic control, hypoglycemia, basal insulin, prandial insulin, insulin dose adjustment
MeSH terms: Assessment of Medication Adherence, Blood Glucose, China, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Female, France, Germany, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Japan, Male, Middle Aged, Spain, Turkey, United States, Health Behavior, Drug Monitoring, Medication Adherence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks